当前位置：
X-MOL 学术
›
Diabetes Obes. Metab.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial.
Diabetes, Obesity and Metabolism ( IF 5.4 ) Pub Date : 2020-02-23 , DOI: 10.1111/dom.14011 Harpreet S Bajaj 1, 2 , Itamar Raz 3 , Ofri Mosenzon 3 , Sabina A Murphy 4 , Aliza Rozenberg 3 , Ilan Yanuv 3 , Deepak L Bhatt 4 , Lawrence A Leiter 5 , Darren K McGuire 6 , John P H Wilding 7 , Ingrid A M Gause-Nilsson 8 , Marc S Sabatine 4 , Stephen D Wiviott 4 , Avivit Cahn 3
Diabetes, Obesity and Metabolism ( IF 5.4 ) Pub Date : 2020-02-23 , DOI: 10.1111/dom.14011 Harpreet S Bajaj 1, 2 , Itamar Raz 3 , Ofri Mosenzon 3 , Sabina A Murphy 4 , Aliza Rozenberg 3 , Ilan Yanuv 3 , Deepak L Bhatt 4 , Lawrence A Leiter 5 , Darren K McGuire 6 , John P H Wilding 7 , Ingrid A M Gause-Nilsson 8 , Marc S Sabatine 4 , Stephen D Wiviott 4 , Avivit Cahn 3
Affiliation
To investigate whether the cardiovascular and renal benefits observed with dapagliflozin in the DECLARE‐TIMI 58 trial are also observed in patients with short and long‐standing diabetes.
中文翻译：
达格列净对短期和长期 2 型糖尿病患者的心血管和肾脏益处：来自 DECLARE-TIMI 58 试验的分析。
研究在 DECLARE-TIMI 58 试验中观察到的达格列净对心血管和肾脏的益处是否也在短期和长期糖尿病患者中观察到。
更新日期：2020-02-23
中文翻译：
达格列净对短期和长期 2 型糖尿病患者的心血管和肾脏益处：来自 DECLARE-TIMI 58 试验的分析。
研究在 DECLARE-TIMI 58 试验中观察到的达格列净对心血管和肾脏的益处是否也在短期和长期糖尿病患者中观察到。
京公网安备 11010802027423号